Jahresbericht 2025/26

Publikationen

• Ahn D D, The N T, Song L H, Müller A, Velavan T P, Seliger B. Elevated soluble HLA-G levels associate with dengue severity in Vietnamese patients. J Med Virol. 2025, 97 (9):e70594. doi: 10.1002/jmv.70594
• Ammar D, Sanges C, Henderson D, Schapitz I, Hudecek M, Luu M, Schüssler-Lenz M, Buchholz C, Franz P, Reiche K, Köhl U, Ifrah N, Quesnel B, Thermeli M, Kersten M J, Locatelli F, D'Amore M L, Bonini C, Casucci M, Philippar U, Doeswijk R, Thielen F, Uyl-de Groot C, Theelen J, Schröder B, Kremer A, Quaranta M, Prosper F, Brulle J van den, Grawunder U, Donnadieu E, Galy A, Ferrand C, Worel N, Busch D, Briones J, Sellner L, Kuball J, Sureda A, Awigena-Cook J. Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. Cytotherapy. 2026, 28 (1):101984. doi: 10.1016/j.jcyt.2025.09.007. Epub 2025 Sep 23
• Andersen J L, Banke S, Fagerberg R, Flamm C, Merkle D, Stadler P F. Pathway realizability in chemical networks. J Comput Biol. 2025, 32 (2): 164-187. doi: 10.1089/cmb.2024.0521
• Arend L, Adamowicz K, Schmidt J R, Burankova Y, Zolotareva O, Tsoy O, Pauling J K, Kalkhof S, Baumbach J,  List M, Laske T. Systematic evaluation of normalization approaches in tandem mass tag and label-free protein quantification data using PRONE. Brief Bioinform. 2025, 26 (3): bbaf201. doi: 10.1093/bib/bbaf201
• Bauer M, Santos P, Wilfer A, Berg E van den, Zietsman A, Vetter M, Kaufhold S, Wickenhauser C, Dos-Santos-Silva I, Chen W C, Cubasch H, Murugan N, McCormack V, Joffe M, Seliger B, Kantelhardt E. HIV status alters immune cell infiltration and activation profile in women with breast cancer. Nat Commun. 2025, 16 (1): 4699. doi: 10.1038/s41467-025-59408-8
• Bloße A, Pirlich M, Dietz A, Möser C, Arnold K, Freitag J, Neumuth T, Smith D M, Kubitschke H, Gaenzle M. Fluorescence-guided surgery in head and neck Squamous cell carcinoma (HNSCC). Int. J. Transl. Med. 2025, 5 (3), 40. doi: 10.3390/ijtm5030040
• Bluhm A, Xiang W, Wien F, Thureau A,  Chevreuil M,  Raynal B,  Geissler S,  Wermann M,  Schilling S, Bénas P, Hartlage-Rübsamen M, Schulze A, Sauter C, Roßner S. Monomers, dimers, and oligomers of pyroglutamate-modified α-Synuclein fragments exhibit distinct biophysical characteristics. ACS Chem Neurosci. 2025, 16 (10): 1919-1936. doi: 10.1021/acschemneuro.5c00106
• Born P, Fandrei D, Wang S Y, Perez-Fernandez C, Fischer L, Ussmann J, Bach E, Hoffmann S, Metzeler K H, Herling M, Herling C, Jentzsch M, Boldt A, Seiffert S, Baber R, Weidner H, Franke G-N, Denecke T, Sabri O, Platzbecker U, Vucinic V, Meyer H J, Kurch L, Merz M. Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma. Hemasphere. 2025, 9 (6): e70159. doi: 10.1002/hem3.70159
• Braun T, Kuschel F, Reiche K, Merz M, Herling M. Emerging T-cell lymphomas after CAR T-cell therapy. Leukemia. 2025, 9 (6): 1337-1341. doi: 10.1038/s41375-025-02574-x
• Braun T, Rade M, Merz M, Klepzig H, Große F, Fandrei D, Pham N-N, Kreuz M, Kuhn C K, Kuschel F, Löffler D, Meinel J, Heger E, Schweinsberg V, Pflug N, Platzbecker U, Hallek M, Holtick U, Köhl U, Scheid C, Reiche K, Herling M, Richardson T. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat Med. 2025, 31 (4): 1145-1153. doi: 10.1038/s41591-025-03499-9
• Burankova Y, Abele M, Bakhtiari M, Toerne C von, Barth T K, Schweizer L, Giesbertz P, Schmidt J R, Kalkhof S, Müller-Deile J, Veelen P A van, Mohammed Y, Hammer E, Arend L, Adamowicz K, Laske T, Hartebrodt A, Frisch T, Meng C, Matschinske J, Späth J, Röttger R, Schwämmle V, Hauck S M, Lichtenthaler S F, Imhof A, Mann M, Ludwig C, Kuster B, Baumbach J, Zolotareva O. Privacy-preserving multicenter differential protein abundance analysis with FedProt. Nat Comput Sci. 2025, 5 (8): 675-688. doi: 10.1038/s43588-025-00832-7
• Cavina L, Alocén Portillo A, Balmer M P A, Dammer J C, Schillemans D, Hamdani S H, Ackerschott B, Dieteren C E J, Martina B E E, Buuren B N M van, Rockstroh A, Ulbert S, Hermkens P H H, Llinàs Brunet M, Gironés D, Feiters M, Rutjes F P J T. Development of lipopeptides as orthoflavivirin inhibitors with low micromolar broad-spectrum antiorthoflaviviral activity. J Med Chem. 2025, 68 (21): 22386-22400. doi: 10.1021/acs.jmedchem.5c01364
• Ciok M, Diener J, Otte F, Feimer J, Nichterlein M, Kalkhof S, Noll M. Biocide-containing facades alter culture-based bacterial and fungal community composition and resistance patterns to octylisothiazolinone. Microorganisms. 2025, 13 (10): 2284. doi: 10.3390/microorganisms13102284
• Coşkuner Leineweber Ö, Pothineni B K, Schumann N, Hofmann U, Möser C, Smith D M, Grundmeier G, Zhang Y, Keller A. Vancomycin-modified DNA origami nanostructures for targeting bacterial pathogens. Small Structures  2025, 6 (12): e202500246. doi: 10.1002/sstr.202500246
• Couto P S, Stibbs D J, Springuel P, Schultz U, Effenberger M, Goldrick S, Navarro-Velázquez S, Juan M, Herbst L, Nießing B, Mestermann K, Sanges C, Hudecek M, Rafiq Q A. Impact of serum/xeno-free medium and cytokine supplementation on CAR-T cell therapy manufacturing in stirred tank bioreactors. Biotechnol J. 2025, 20 (9): e70114. doi: 10.1002/biot.70114
• De Angelis B, D'Amore M L, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz J R, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C. European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring. Front Immunol. 2025, 16: 1567582. doi: 10.3389/fimmu.2025.1567582
• Di Giacomo A M, Subudhi S, Vos W, Andreatta M, Carmona S, McTavish W, Seliger B, Ibrahim R, Lahn M, Smith M, Eggermont A, Fox B A, Maio M. Perspectives on the role of “-Omics” in predicting response to immunotherapy. Eur J Cancer. 2025, 220: 115393. doi: 10.1016/j.ejca.2025.115393
• Eick S, Taudte N, Ramsbeck D, Magdon A, Sculean A, Potempa J, Buchholz M. Effect of a bacterial glutaminyl cyclase inhibitor on multi-species-biofilms. Front. Oral Health, 01 December 2025, Sec. Oral Infections and Microbes, Volume 6 - 2025. doi: 10.3389/froh.2025.1716625
• Fanti Z, Braumann U-D, Rauscher F G, Ebert T, Bribiesca E, Martinez-Perez M E. Slope chain code-based scale-independent tortuosity measurement on retinal vessels. Exp Eye Res. 2025, 254: 110286. doi: 10.1016/j.exer.2025.110286
• Ferle M, Grieb N, Kreuz M, Ader J, Goldschmidt H, Mai E K, Bertsch U, Platzbecker U, Neumuth T, Reiche K, Oeser A, Merz M. Predicting progression events in multiple myeloma from routine blood work. NPJ Digit Med. 2025, 8 (1): 231. doi: 10.1038/s41746-025-01636-9
• Fertey J, Makert G R, Becker P, Finkensieper J, Ulbert S. Low-energy electron irradiation inactivates viruses in serum and maintains growth-promoting properties in cell culture. Appl Biosaf. 2025, 30 (3): 264-271. doi: 10.1089/apb.2024.0031
• Filippi Xavier L, Gacesa R, Oliveira Da Rocha G H, Broering M F, Scharf P, Silva Lima F da, Faber K N, Harmsen H, Hoffmann C, Poliselli Farsky S H. Annexin A1 levels affect microbiota in health and DSS-induced colitis/inflammatory bowel disease development. Front. Immunol 2025, 16: 1679071. doi: 10.3389/fimmu.2025.1679071
• Friedrich VD, Neier K, Müller K, Fogal B, Loncova Z, Rade M, Shoaib M, Köhl U, Hoyt K, Pande P, Blanchard L, Raymond E, Scholz M, Reiche K, Kirsten H. Deep learning-aided inter-species-comparison reveals shared and distinct molecular patterns in cynomolgus monkey and humans following non-specific T cell activation. Front Immunol. 2025, 16: 1603716. doi: 10.3389/fimmu.2025.1603716
• Gogesch P, Iannazzo S O, Rupp N, Rom J, Kreuz M, Reiche K, Anzaghe M, Waibler Z, on behalf the imSAVAR Consortium. Immune cells play a critical role in cytokine- and endotoxin-mediated endothelial permeability. PLoS One. 2025, 20 (8): e0329700. doi: 10.1371/journal.pone.0329700
• Haupt J, Keminer O, Neser C, Windshügel B, Wiltzsch V, Schmidt J, Pliushcheuskaya P, Künze G, Scholz U, Müller C, Oliveira da Rocha G H, Biermann M, Zdzieblo D, Metzger M, Schiefke I, Neurath M, Siegmund B, Claussen C, Köhl U, Geisslinger G, Buchholz M, Kalkhof S, Lehmann J. Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing. Biochem Pharmacol. 2025, 240: 117066. doi: 10.1016/j.bcp.2025.117066
• Horbas H, Bauer M, Eckert A, Bethmann D, Wilfer A, Seliger B, Wickenhauser C. Comparison of manual versus QuPath software-based immunohistochemical scoring using oral squamous cell carcinoma as a model. J Histochem Cytochem. 2025, 73 (5-6): 181-196. doi: 10.1369/00221554251335698
• Jaeckel E, Friedman S L, Hudecek M, Protzer U. Chimeric antigen receptor (CAR) T-cell therapy: engineering immune cells to treat liver diseases. Review J Hepatol. 2025, 83 (5): 1156-1171. doi: 10.1016/j.jhep.2025.06.007
• Keitel V, Kreissl MC, Goetze T, Dröge C, Kuhn CK, Pham NN, Löffler D, Borie D, Schreiber J, Boettcher M, Hippe K, Pech M, Mikusko M, Köhl U, Walther D, Reiche K, Mougiakakos D. CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement. J Hepatol. 2025 Dec 8:S0168-8278(25)02711-4. doi: 10.1016/j.jhep.2025.11.027
• Kiefer N, Klein J, Beyer F, Burghardt B, Rohr M, Klein M, Burghardt M, Noll M, Kalkhof S. Experimental and computational identification of essential parameters governing biocide distribution in soil. Environ Toxicol Chem. 2025, 44 (10): 3037-3050. doi: 10.1093/etojnl/vgaf156
• Kiefer N, Klein J, Rohr M, Noll M, Burkhart M, Klein M, Kalkhof S. Simulation of the biocide distribution in soil using PELMO coupled with COMLEAM. Environ Sci Pollut Res Int. 2025, 32 (5): 2425-2440. doi: 10.1007/s11356-024-35760-y
• Kirchhoff H, Schoenherr C, Fleischer L, Schweighart E K, Esser R, Talbot S R, Schambach A, Köhl U, Heidenreich O, Eder M, Scherr M. Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia. Hemasphere. 2025, 9 (10): e70238. doi: 10.1002/hem3.70238
• Kitte R, Serfling R, Blache U, Seitz C, Schrader S, Köhl U, Fricke S, Bär C, Tretbar S U. Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation. Int J Mol Sci. 2025, 26 (3): 965. doi: 10.3390/ijms26030965
• Körtge A, Kamper C, Klinkmann G, Wasserkort R, Mitzner S. In vitro assessment of drug adsorption profiles during hemoadsorption therapy. Blood Purif. 2025, 54 (4-5): 218-225. doi: 10.1159/000545120
• Krames W E A, Dayi D I, Kaiser L, Riester O, Himmelhaus M, Csuk R, Deigner H-P. WGM sensors for future diagnostics: small molecules to whole organisms. Biosens. Bioelectron. (UK). 2025, 26: 100671. doi: 10.1016/j.biosx.2025.100671
• Kurz K S, Steinlein S, Kreuz M, Ziepert M, Staiger A M, Barth T F E, Möller P, Bernd H-W, Feller A C, Richter J, Klapper W, Stein H, Hartmann S, Hansmann M-L, Trümper L, Loeffler M, Schmitz N, Rosenwald A, Ott G, Horn H, DSHNHL/GLA. Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: results from clinical trials of the DSHNHL/GLA. Hemasphere. 2025, 9 (3): e70093. doi: 10.1002/hem3.70093
• Lehmann S, Lange U G, Oberbach A, Retschlag U, Morgenroth R, Busse H, Prettin C, Petroff D, Seidemann L, Blüher M, Dietrich A. The effect of 6 months of structured strength or endurance exercise program on weight loss after gastric bypass surgery in a randomized controlled trial. Langenbecks Arch Surg. 2025, ;410 (1): 194. doi: 10.1007/s00423-025-03731-7
• Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche J-B, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, Vos J de, Diana J, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I. Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium. Bone Marrow Transplant. 2025, 60 (9): 1209-1217. doi: 10.1038/s41409-025-02637-8
• Mazein A, Lopata O, Reiche K, Sewald K, Alb M, Sakellariou C, Gogesch P, Morgan H, Neuhaus V, Pham N-N, Sommer C, Perkins E, Fogal B, Shoaib M, Schneider R, Satagopam V, Ostaszewski M. An explorable model of an adverse outcome pathway of cytokine release syndrome related to the administration of immunomodulatory biotherapeutics and cellular therapies. Front Immunol. 2025, 16: 1601670. doi: 10.3389/fimmu.2025.1601670
• Nelz S-C, Lück E, Schölzel A, Sauer M, Heskamp J, Doss S. Ex vivo plasma application on human brain microvascular endothelial-like cells for blood-brain barrier modeling. Int J Mol Sci. 2025, 26 (7): 3334. doi: 10.3390/ijms26073334
• Nguyen T T, Ho P, Staudt S, Gregoire C, Ziegler-Martin K, Jassin M, Block A, Hudecek M, Melenhorst J, Caers J, Luu M. Fine tuning towards the next generation of engineered T cells. Nat Biomed Eng. 2025, 9 (10): 1610-1631. doi: 10.1038/s41551-025-01492-8
• Nichterlein M, Kiefer N, Hohner J, Stapf D, Schatz M, Noll M, Kalkhof S. Encapsulated biocides in facade materials impact leaching and UV stability, resulting in lower aquatic toxicity of the eluates. Environ Sci Pollut Res Int. 2025, 32 (27): 16324-16339. doi: 10.1007/s11356-025-36647-2
• Peña‑Rodríguez A, Ramírez‑Sánchez I, Leptihn S, Quiroz‑Guzmán E. A novel vibriophage vB_Vp_PvVp04 against pathogenic Vibrio parahaemolyticus and its formulation for inclusion in shrimp feed. Aquaculture Int. 2025, 33: 117. doi: 10.1007/s10499-024-01797-6
• Pennings E R, Spanjaart A M, Thielen F W, Oerlemans S, Fleischer A, Sanges C, Gomes Da Silva M, Cabrerizo Y, Lecot P, Roux-Opstaele L, Dreuillet C, Gonzalez-Marcano E, Millán O, Jaeger U, Delgado J, Luu M, Huber B, Lorrain M, Galhardas Pina M, Kremer A, Bolanos N, Clavreul S, Nier S, Liu R D K, Lissenberg-Witte B I, Anguille S, Robin M, Morris E C, Sureda A, Préau M, Pannard M, Bock G H de, Wagers S S, Trebeden-Negre H, Maucort-Boulch D, Hudecek M, Uyl-de Groot C A, Kersten M. Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood Adv. 2025, 9 (24): 6380-6393. doi: 10.1182/bloodadvances.2025017081
• Petri K, D'Ippolito E, Künkele A, Köhl U, Busch D H, Einsele H, Hudecek M. Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities. Nat Rev Clin Oncol. 2025, 22 (12): 902-923. doi: 10.1038/s41571-025-01072-4
• Petroni G, Galassi C, Gouin K H, Chen H-H, Buqué A, Bloy N, Yamazaki T, Sato A, Beltrán-Visiedo M, Campia G, Jiménez-Cortegana C, Shah A, Kirchmair A, Massa C, Wickenhauser C, de Andrea C E, Navarro-Rubio B, Serrano-Mendioroz I, Navarro Manzano E, Satty A M, Rippon B, Finotello F, Trajanoski Z, Zhou X K, Scandura J M, García-Martínez E, Ayala de la Peña F, Rodríguez-Ruiz M E, Seliger B, Sánchez-Margalet V, de la Cruz-Merino L, Basho R K, Shiao S L, McArthur H L, Formenti S C, Knott S R V, Galluzzi L. IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages. Nat Cancer. 2025, 6 (10): 1656-1675. doi: 10.1038/s43018-025-01007-z
• Popp G, Jöckel L, Kläs M, Wiener T, Hilger N, Stumpf N, Groß J, Dünkel A, Blache U, Fricke S, Franz P. A user-centric approach to reliable automated flow cytometry data analysis for biomedical applications. Cytometry A. 2025, 107 (2): 111-125. doi: 10.1002/cyto.a.24913
• Rade M, Fandrei D, Kreuz M, Seiffert S, Grahnert A, Friedrich M, Wiemers T, Born P, Fischer L, Weidner H, Hofbauer LC, Baber R, Wang SY, Bach E, Hoffmann S, Scolnick J, Friedrich M, Keramati F, Brazda P, Sebestyen Z, Kuball J, Alb M, Scheller L, Hudecek M, Einsele H, Metzeler KH, Herling M, Herling CD, Jentzsch M, Franke GN, Boldt A, Köhl U, Platzbecker U, Vucinic V, Reiche K, Merz M. A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma. Cancer Cell. 2025, S1535-6108 (25) 00490-8. doi: 10.1016/j.ccell.2025.10.014
• Reis T, Ramírez-Guerrero G, Pecoits-Filho R, Lorenzin A, Cal M de, Corradi V, Klinkmann G, Ronco F, Neves F A R, Bellomo R, Ronco C. Iodinated contrast adsorption in cartridges with styrene-divinylbenzene sorbent. Artif Organs. 2025, 49 (5): 813-819. doi: 10.1111/aor.14949
• Reiß F, Kiefer N, Tanunchai B, Reiss P, Kalkhof S, Noll M. Continuous intake of facade eluates affects active and total soil Microbiome. Biol. Fertil. Soils. 2025, 62: 75-95. doi: 10.1007/s00374-025-01955-9
• Renner A, Finkbeiner M S C, Haas F V, Stahringer A, Lindow M, Delaroque N, Szardenings M, Fricke S, Köhl U, Engeland C E, Schmiedel D. Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy. Mol Ther Oncol. 2025, 33 (4): 201043. doi: 10.1016/j.omton.2025.201043
• Riester Z, Surowka M, Seifert N, Darowski D, Ghosh A, Spieler P, Weber J, Gianotti R, Freitag F, Alb M, Nerreter T, Gerhard-Hartmann E, Rosenwald A, Sauer M, Moessner E, Einsele H, Ferrara-Koller C, Klein C, Hudecek M, Danhof S. Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma. Mol Ther. 2025, S1525-0016(25)00867-6. doi: 10.1016/j.ymthe.2025.10.046
• Ritter J, Falckenhayn C, Qi M, Gather L, Gutjahr D, Schmidt J, Simm S, Kalkhof S, Hildebrand J, Bosch T, Winnefeld M, Grönniger E, Siracusa A. Systemic factors in young human serum influence in vitro responses of human skin and bone marrow-derived blood cells in a microphysiological co-culture system. Aging (Albany NY). 2025, 17 (7): 1784-1809. doi: 10.18632/aging.206288
• Roßbach L, Eichenberg T, Pietzsch N, Franz P, Fricke S, Sieg R, Dünkel A, Adlkofer KS. "Live" cell shipment-a forward-looking transport option for cryo-sensitive cell-based therapies. Front Bioeng Biotechnol. 2025, 13: 1706927. doi: 10.3389/fbioe.2025.1706927
• Salti H, Nelz S-C, Lichtwark S, Pohl C, Kramer L, Lorenz M, Lemcke H, Doss S, Mitzner S, Wasserkort R. Recellularization of Scaffolds derived from precision-cut kidney slices. Biomed Mater. 2025, 20 (6). doi: 10.1088/1748-605X/ae05a4
• Sandetskaya N, Kölsch A, Mattern K, Vater V, Kuhlmeier D, Priller F. CampyTube: Seamless Integration of a Molecular Test and Lateral Flow Detection of Campylobacter in a Single Vial. Biosensors (Basel). 2025, 15 (8), 497. doi: 10.3390/bios15080497 
• Sattler T, Benka B, Zimpernik I, Pürrer S, Waldner K, Duscher G G, Kuffer-Rosewick A, Fertey J, Ulbert S, Schmoll F. Retrospective cross-sectional study of occupational infection risk with zoonotic pathogens in austrian veterinary practitioners in the year 2022. Vet Med Sci. 2025, 11 (5): e70485. doi: 10.1002/vms3.70485
• Scheller L, Zhou X, Loeffler-Wirth H, Kreuz M, Kadel SK, Schimanski S, Schulze H, Ruckdeschel A, Eisele F, Konetzki V, Jornet Culubret M, Merz M, Mersi J, Waldschmidt J, Danhof S, Köhl U, Kortüm KM, Rasche L, Einsele H, Düll J, Topp MS, Hudecek M, Reiche K, Alb M. Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy. Hemasphere. 2025, 9 (12): e70267. doi: 10.1002/hem3.70267
• Schindler-Wnek K, Stahringer A, Heimer N, Köhl U, Fricke S, Schmiedel D. Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies. Oncoimmunology. 2025, 14 (1): 2546443. doi: 10.1080/2162402X.2025.2546443
• Schmidt J, Sopel N, Rist C, Ohs A, Dawid L, Simm S, Catanese L, Rupprecht H, Jobst-Schwan T, Lehmann J, Daniel C, Kalkhof S, Schiffer M, Müller-Deile J. Dysregulated protease homeostasis defines primary focal segmental glomerulosclerosis. Kidney360. 2025. ahead of print. doi: 10.34067/KID.0000001021 
• Schwarzer A, Ziegler U, Fertey J, Kreuz M, Vahlenkamp T W, Groschup M H, Ulbert S. Serological differentiation of West Nile, Usutu, and tick-borne encephalitis virus antibodies in birds and horses using mutant E protein ELISAs. Sci Rep. 2025, 15 (1): 28752. doi: 10.1038/s41598-025-14448-4
• Seiffert S, Blaudszun, A-R, Shibru B, Körfer J, Köhl U, Fricke S, Sack U, Boldt A. Differential expression of immune checkpoints TIM-3, LAG-3, TIGIT, and Siglec-7 on circulating natural killer cells - insights from healthy donors compared to gastric cancer patients. Oncol Res Treat. 2025, 48 (10): 585-600. doi: 10.1159/000545429
• Seiffert S, Kirchberg J, Bach E, Menger V, Brückner M, Sack U, Köhl U, Platzbecker U, Boldt A, Herling M, Vučinić V. Extracorporeal photopheresis - new insights into an old procedure. Transfus Med. 2025 Jun 10. doi: doi: 10.1111/tme.13156
• Seliger B, Massa C. CyTOF as a suitable tool for stratification and monitoring of cancer patients. J Transl Med. 2025, 23 (1): 724. doi: 10.1186/s12967-025-06764-0
• Selpiev Z, Leptihn S, Müsken M, Loh B. Deciphering shared receptor usage in genomically unrelated bacteriophages infecting hypervirulent Klebsiella pneumoniae K1 ST23. FEMS Microbes. 2025, 6: xtaf014. doi: 10.1093/femsmc/xtaf014
• Song Y, Lee S, Heo S-W, Spohn J, Schmiedel D, Heo T, Kim S, Park J, Seo H R. HO-1197 as a multifaceted therapeutic: targeting the cell cycle, angiogenesis, metastasis, and tumor immunity in hepatocellular carcinoma. Int J Mol Sci. 2025, 26 (21): 10329. doi: 10.3390/ijms262110329
• Stubenvoll A, Schmidt M, Moeller J, Lingner Chango M A, Schultz C, Antoniadou O, Loeffler-Wirth H, Bernhart S, Große F, Thier B, Paschen A, Anderegg U, Simon J C, Ziemer M, Schoeder C T, Binder H, Kunz M. Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity. Cancer Commun (Lond). 2025,  45 (4): 465-470. doi: 10.1002/cac2.12651
• Subbarayan K, Bieber H, Massa C, Rodríguez F A E, Hossain S M AA,  Neuder L,  Wahbi W, Salo T, Tretbar S, Al-Samadi A, Seliger B. Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers. J Transl Med. 2025, 23 (1): 294. doi: 10.1186/s12967-025-06177-z
• Tony L T, Stabile A, Schauer M P, Hudecek M, Weber J. CAR-T cell therapy for solid tumors. Transfus Med Hemother. 2025, 52 (1): 96–108. doi: 10.1159/000542438
• Udinotti M, Sieboldts U, Bauer M, Vaxevanis C, Asiminas A, Lorenz K, Dierks C, Wickenhauser C, Seliger B. Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancer. J Transl Med. 2025, 23 (1): 1284. doi: 10.1186/s12967-025-07307-3
• Uhlmann L, Pierer M, Krasselt M, Franke G, Zeidler R, Sabri O, Denecke T, Sack U, Köhl U, Boldt A, Borie D, Wagner U, Platzbecker U, Vucinic V. Effective use of anti-CD19 chimeric antigen receptor T cells in a case of treatment-resistant granulomatosis with polyangiitis. Ann Rheum Dis. 2025, 84 (7): 1280-1283. doi: 10.1016/j.ard.2025.04.029
• Weber J, Rade M, Michael J, Tony L T, Freitag F, Spieler P, Müller C, Kalogirou C, Mainz L, Lehmann J, Klopfleisch R, Rosenfeldt M T, Danhof S, Kortüm K M, Köhl U, Einsele H, Rader C, Reiche K, Nerreter T, Hudecek M. ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell Rep Med. 2025, 6 (10): 102400. doi: 10.1016/j.xcrm.2025.102400
• Wegner V D, Feile A, Alb M, Hudecek M, Hewitt P, Mosig A S. Short-chain fatty acids modulate anti-ROR1 CAR T-cell function and exhaustion in an intestinal adenocarcinoma-on-chip model. Adv Healthc Mater. 2025 May;14(13):e2405003. Epub 2025 Apr 18. doi: 10.1002/adhm.202405003
• Weirauch U, Kreuz M, Birkenbihl C, Alb M, Quaranta M, Calzone L, Orozco-Ruiz S, Binder S, Fischer L, Clavreul S, Maguri M, Ferle M, Rade M, Azarias G, Hydren J R, Jamarik J, Schwarz D, Sebestyen Z, Kuball J, Popp G, Antoine C, Knockaert M, Schoeder C T, Fandrei D, Sanges C, Radvilas V, Gagelmann N, Rückert M, Penack O, Fricke S, Schmidt A, Ward C, Steinbeisser C, Van Gyseghem J-M, Niarakis A, Garderet L, Hudecek M, Neumuth T, Platzbecker U, Köhl U, Demlova R, Kremer A, Franke S, Fröhlich H, Merz M, Reiche K, CERTAINTY Consortium. Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies. NPJ Digit Med. 2025, 8 (1): 493. doi: 10.1038/s41746-025-01809-6
• Wiemers T, Ferle M,  Ader J, Sotikova V, Fandrei D, Grieb N, Fischer L, Born P, Weidner H, Wang S Y, Jentzsch M, Franke G-N, Herling C, Metzeler K, Herling M,  Heyn S,  Denecke T, Reiche K, Platzbecker U,  Vucinic V, Neumuth T, Meyer H-J,  Merz M. Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma. Transplant Cell Ther. 2025, 31 (10): 789-803. doi: 10.1016/j.jtct.2025.07.003
• Wiltzsch V, Schmidt J R, Adamowicz K, Lauterbach T, Lehmann J, Baumbach J, Laske T, Kalkhof S. Systematic comparison of bone proteome extraction methods to allow for integrated proteomics-metabolomics correlation. J Proteome Res. 2025, 24 (9): 4362-4376. doi: 10.1021/acs.jproteome.4c01060
• Yanik S D, Jameel K J, Rohde S, Bürger P, Bülthoff E, Grunwald T, Kronsbein J, Koch A, Edwards M R, Tenbusch M, Knobloch J. Cytokine production of mononuclear leukocytes in response to respiratory syncytial virus is increased in COPD but suppressed in non-COPD tobacco smokers. Mol Med. 2025 Jun 12;31(1):237. doi: 10.1186/s10020-025-01277-4
• Ye J L, Grieger K, Lu D, Brandenberger C, Juchem M, Jordan M, Oehlsen L, Zardo P, Werlein C, Hesse C, Sewald K, Tretbar S, Thum T, Chatterjee S, Bär C. Telomerase modRNA offers a novel RNA-based approachto treat human pulmonary fibrosis. Aging Cell. 2025, 24 (11): e70240. doi: 10.1111/acel.70240

• Altattan B, Möser C, Smith D. Modification of DNA nanostructures with functional peptides through copper-free click chemistry. Zuccheri, G. (eds) DNA Nanotechnology. Methods in Molecular Biology, vol 2901. Humana, New York, NY. pp 179–189. doi: 10.1007/978-1-0716-4394-5_14
• Bauer M, Wilfer A, Zöllig C, Wickenhauser C, Seliger B. Multiparametric staining - combined application of immunofluorescence and in-situ hybridization. In: Methods in cell biology. Elsevier, 2025, 201, Seite 155-168. doi: 10.1016/bs.mcb.2025.09.001
• Udinotti M, Siebolts U, Vaxevanis C, Seliger B. Extracellular matrix and morphology assessment method on live 3D spheroids of thyroid carcinoma. In: Methods in cell biology. Elsevier, 2025, 201, Seite 169-184. doi: 10.1016/bs.mcb.2025.09.011
• Uhlig J, Schmiedel D, Tretbar S, Dünkel A. Advances in the manufacturing of CAR-NK cells for cancer immunotherapy. In: Langel, Ü. (ed): Cancer-targeted drug delivery. Methods in pharmacology and toxicology. Humana, 2025, Seite 63-81. doi: 10.1007/978-1-0716-4374-7_4
• Vaxevanis C, Udinoti M, Kokoretsis D, Wilfer A, Bauer M, Wickenhauser C, Seliger B. Hema-CRISPR: a clone-based protocol for effective genetic editing of hematopoietic stem cells. In: Methods in cell biology. Elsevier, 2025, 201, Seite 185-194. doi: 10.1016/bs.mcb.2025.09.002

• Bär C, Blache U, Tretbar S. Advancing mRNA-based cell therapies: the crucial role of mRNA optimization for therapeutic efficacy. Nucleic Acid Insights 2025, 1 (2): 1–5. doi: 10.18609/nuc.2025.001. https://www.insights.bio/nucleic-acid-insights/journal/article/3335/advancing-mrnabased-cell-therapies-the-crucial-role-of-mrna-optimization-for-therapeutic-efficacy
• Ferle M, Grieb N, Kreuz M, Ader J, Goldschmidt H, Mai E K, Bertsch U, Platzbecker U, Neumuth T, Reiche K, Oeser A, Merz M. Publisher Correction: Predicting progression events in multiple myeloma from routine blood work. NPJ Digit Med. 2025, 8 (1): 316. doi: 10.1038/s41746-025-01719-7
• He J, Shi Q, Chen Z, Zhang W, Lan P, Xu Q, Hu H, Chen Q, Fan J, Jiang Y, Loh B, Leptihn S, Zou Q, Zhang J, Yu Y, Hua X. Corrigendum to “Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae” [Drug Resist. Updat. 66 (2023) 100891]. Drug Resist Updat. 2025, 81: 101244. doi: 10.1016/j.drup.2025.101244
• Hudecek M. Boosting immune cells to combat cancer using CRISPR engineering and large-scale in vivo testing. Nature. 2025, 646: 808-809. doi: 10.1038/d41586-025-02595-7
• Klinkmann G, Marcello M, Husain-Syed F, o Ramírez Guerrero G, Reis T, Ronco C. Comment: ineffectiveness of hemoadsorption in large animals with abdominal sepsis - a randomized controlled porcine study. Intensive Care Med Exp. 2025, 13 (1): 76. doi: 10.1186/s40635-025-00764-6
• Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche J-B, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, Vos J de, Diana J, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I. Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (Bone Marrow Transplantation, (2025), 10.1038/s41409-025-02637-8). Bone Marrow Transplant. 2025, 60 (1300). doi: 10.1038/s41409-025-02672-5
• Merz M, Gagelmann N. GSI: myeloma - cold case closed? Blood. 2025, 145 (2): 148-149. doi: 10.1182/blood.2024027056
• Merz M. Losing CD38 in myeloma. Blood. 2025, 146 (13): 1529-1530. doi: 10.1182/blood.2025029889
• Petroni G, Galassi C, Gouin K H, Chen H-H, Buqué A, Bloy N, Yamazaki T, Sato A, Beltrán-Visiedo M, Campia G, Jiménez-Cortegana C, Shah A, Kirchmair A, Massa C, Wickenhauser C, de Andrea C E, Navarro-Rubio B, Serrano-Mendioroz I, Navarro Manzano E, Satty A M, Rippon B, Finotello F, Trajanoski Z, Zhou X K, Scandura J M, García-Martínez E, Ayala de la Peña F, Rodríguez-Ruiz M E, Seliger B, Sánchez-Margalet V, de la Cruz-Merino L, Basho R K, Shiao S L, McArthur H L, Formenti S C, Knott S R V, Galluzzi L. Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages (Nature Cancer, (2025), 10.1038/s43018-025-01007-z). Nat Cancer. 2025, 6 (10): 1754. doi: 10.1038/s43018-025-01036-8
• Reiche K, Weirauch U, Kreuz M, FischerL, Gras L, Neumuth T, Platzecker U, Köhl U, Demlova R, Kremer A, Fröhlich H, Franke S, Merz M, CERTAINTY Consortium. Virtual twins for personalised CAR T-cell therapy in myeloma. Lancet Haematol. 2025, 12 (7): e490-e491. doi: 10.1016/S2352-3026(25)00170-X
• Salti H, Kramer L, Nelz S-C, Lorenz M, Breitrück A, Hofrichter J, Frank M, Schulz K, Mitzner S, Wasserkort R. Corrigendum: Decellularization of precision-cut kidney slices-application of physical and chemical methods (2023 Biomed. Mater. 18 025004). Biomed Mater. 2025, 20 (2). doi: 10.1088/1748-605X/adae47
• Sauer M. Liver failure – reasons, diagnostics and concepts of therapy = Leberversagen – Ursachen, Diagnostik und Therapiekonzepte. Anästh Intensivmed. 2025, 66: 461–471. doi: 10.19224/ai2025.461
• Schindler-Wnek K, Schmiedel D. CAR-NK-Zellen: die nächste Innovation der Krebsimmuntherapie? BIOspektrum. 2025, 31: 280–283. doi: 10.1007/s12268-025-2470-4
• Weirauch U, Kämpf C, Reiche K. Was wäre, wenn…: Szenarien der Zelltherapie digital durchgespielt. IM+io Best und Next Practices aus Digitalisierung, Management, Wirtschaft. 2025, 2. https://www.im-io.de/was-waere-wenn-szenarien-der-zelltherapie-digital-durchgespielt/

• Alb M, Scheller L, Einsele H, Maulana TI, Teufel C, Loskill P, Weener HJ, van der Meer AD, Sewald K, Kreuz M, Löffler-Wirth H, Weirauch U, Reiche K, Köhl U, Hudecek M. Innovative strategies to improve nonclinical safety assessment of CAR T cells and immunomodulatory biotherapeutics: the IMSAVAR project. EHA-EBMT 7th European CAR T-cell Meeting, 6.-8.2.2025, Straßburg, Frankreich
• Alb M, Scheller L, Einsele H, Maulana TI, Teufel C, Loskill P, Weener HJ, van der Meer AD, Sewald K, Kreuz M, Löffler-Wirth H, Weirauch U, Reiche K, Köhl U, Hudecek M. Innovative strategies to improve nonclinical safety assessment of CAR T cells and immunomodulatory biotherapeutics: the IMSAVAR project. 5th International Conference on Lymphocyte Engineering (ICLE), 20.-22.2.2025, München
• Allelein S, Aerchlimann K, Arbaciauskaite S, Mytzka N, Kölsch A, Kuhlmeier D. Extracellular vesicles in liquid biopsy: advancing early disease detection. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Bauer BU, Ganter M, Fertey J, Makert GR, Mertens-Scholz K, Knittler MR. Q fever vaccines – a veterinary perspective. Q Fever Symposium, 14.-15.6.2025, Byron Bay, Australien
• Bräuning S, Schiefer D, Wußmann M, Greiser S, Fricke S, Köhl U, Blache U, Tretbar S. mRNA technology for the development of CAR-T cells targeting fibrotic diseases. International Conference on Lymphocyte Engineering (ICLE), 20.-22.2.2025, München
• Breuer J, Schmid T. AAV workshop - quality by design for AAV process development. AAV Online Workshop, 17.7.2025
• Breuer J, Schmid T. Quality by design for AAV process development. AAV Meeting 2025, 1.4.2025, Leipzig
• Bülow M, Salti H, Kamper C, Schölzel A, Lichtwark S, Fürst S, Heskamp J, Doss S. OAT-1-vesicles as selective anion transport systems. NLSEV - Netherlands Society for Extracellular Vesicles, 24.-25.11.2025, Amsterdam, Niederlande 
• Burghardt BM , Schmidt JR, Lehmann J, Kalkhof S. More from less - workflow for the quantification of over 1000 proteins from 1 µL of murine neat plasma. Jahrestagung der Deutschen Gesellschaft für Massenspektrometrie (DGMS), 4.-7.3.2025, Göttingen
• Burghardt BM, Kubat J, Schmidt JR, Wach J, Lehmann J, Güresir E, Schulz-Siegmund M , Kalkhof S. Method development for the in-depth analysis of the human cranial proteome - towards the correlation of the human cranial proteome to bone regeneration following neurosurgical procedures. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig 
• Çetin E, Freitag J, von Auw N, Warncke P, Papp TE, Parhiz H, Tretbar US. In vitro characterization of CD5 targeted lipid nanoparticles for precision delivery. Fraunhofer IZI PhD Day, 11.6.2025, Leipzig
• Çetin E, Papp TE, Parhiz H, Bär C, Tretbar S. In vitro characterization of CD5 targeted lipid nanoparticles for precision delivery. Fraunhofer CIMD Symposium "RNA-Based Therapeutics", 10.-11.9.2025, Hannover
• Dilz J, Issmail L, Possardt E, Khan M M, Grote V, Grunwald T, Mahour R, Uhlig N. Identification and evaluation of anti-infective  compounds in human breast milk. Leibniz Conference on Bioactive Compounds, 9.-10.4.2025, Großbeeren 
• Dilz J, Issmail L, Possardt E, Khan M M, Grote V, Grunwald T, Mahour R, Uhlig N. Identification and evaluation of anti-infective  compounds in human breast milk. Glycosciences Summer School, 1.-5.6.2025, Groningen, Niederlande
• Dilz J, Issmail L, Possardt E, Khan M M, Grote V, Grunwald T, Mahour R, Uhlig N. Identification and evaluation of anti-infective  compounds in human breast milk. Fraunhofer IZI PhD Day, 11.6.2025, Leipzig
• Eberlein V, Bayer L, Uhlig N, Grunwald T. Viral trojan horses: non-human papillomavirus capsids as mucosal vaccine vector against RSV. NDP-VIP course on Antivirals – Mechanisms, Resistance, and Innovation, 18.-20.8.2025, Uddevalla, Schweden
• Eberlein V, Bayer L, Uhlig N, Grunwald T. Viral trojan horses: non-human papillomavirus capsids as mucosal vaccine vector against RSV. 22nd Smögen Summer Symposium on Virology, 21.-23.8.2025, Smögen, Schweden
• Eberlein V, Bayer L, Uhlig N, Grunwald T. Viral trojan horses: non-human papillomavirus capsids as mucosal vaccine vector against RSV. GfV Workshop Virale Vectors for Gene Therapy and Vaccination, 20.-21.11.2025, Erlangen
• Eberlein V, Frischbutter S, Obernolte O, Büning H, Hesse C, Scheffel J, Grunwald T. AAV-mediated expression of therapeutic antibodies via minimal invasive application. Fraunhofer CMD Summer School 2025, 22.-24.9.2025, Berlin
• Eberlein V, Frischbutter S, Obernolte O, Büning H, Hesse C, Scheffel J, Grunwald T. AAV-mediated expression of therapeutic antibodies via minimal invasive application. AAV Meeting Leipzig, 1.-2.4.2025, Leipzig
• Eberlein V, Frischbutter S, Obernolte O, Büning H, Hesse C, Scheffel J, Grunwald T. AAV-mediated expression of therapeutic antibodies via minimal invasive applicationAAV-mediated expression of therapeutic antibodies via minimal invasive application. 34th Annual Meeting of the Coviety for Virology, 4.-7.3.2025, Hamburg
• Fandrei D, Seiffert D, Kuhn C, Rade M, van Vliet E, von Landenberg-Rohberg V, Meggendorfer M, Fischer L, Kreuz M, Löffler D, Blumert C, Grahnert A, Friedrich M, Born P, Wiemers T, Skerbek E-C, Jäger K, Greiser S, Baber R, Wang SY, Heyn S, Franke G-N, Boldt A, Schmiedel D, Böttcher S, Herling M, Kuball J, Truger M, Haferlach T, Krönke J, Platzbecker U, Metzeler K, Köhl U, Bohl S, Vucinic V, Sebestyen Z, Reiche K, Merz M. Spatiotemporal and genetic tracking of long-term persisting CAR-T cells following ciltacabtagene autoleucel treatment for multiple myeloma reveals molecular insights into late-onset toxicities. 67th ASH Annual Meeting and Exposition, 6.-9.12.2025, Orlando, Florida, USA
• Feigl FF, Fricke S, Olweus, J, Koehl, U, Schmiedel D. Generation of TCR-NK cells with enhanced co-signaling as allogeneic cell therapy for AML. ESGCT Annual Congress, 7.-10.10.2025, Sevilla, Spanien
• Feigl FF, Fricke S, Olweus, J, Koehl, U, Schmiedel D. Generation of TCR-NK cells with enhanced co-signaling as allogeneic cell therapy for AML. ICLE, 20.-22.2.2025, München
• Fertey J, Makert GR, Issmail L, Thoma M, Schopf S, Grunwald T,  Ulbert S. Low energy electron irradiation for the inactivation of pathogens in liquids for vaccine production. 19th Vaccine Congress, 7.-10.9.2025, Kyoto, Japan
• Fertey J. Low energy electron irradiation for fast inactivation of pathogens in liquids. World Vaccine Congress, 21.-24.4.2025, Washington, DC, USA 
• Fischer M, Mattern K, Menge A, Lotke R, Fertey J, Eckert U, Bernstein R, Otto M, Lachmann I,  Schmidt MP. Replikationstechnologien für den Einsatz biokompatibler, nachhaltiger Materialien in der Point-of-Care-Diagnostik. Fachtagung Technomer 2025, 6.-7.11.2025, Chemnitz
• Flores Naranjo E, Hinze S, Freitag J, Arnold K, Schönfelder J, Smith DM. Volatolomic and biomechanical analysis as windows into immune cell function. CCCG Forschungs-Retreat 2025, 14.-15.8.2025, Leipzig
• Franz P. Automatisierte Produktionstechnologien mRNA-abgeleiteter Impfstoffe und Zell- & Gentherapeutika: Leitprojekt RNAuto. Fraunhofer-Symposium »Netzwert«, 20.2.2025, München
• Franz P. Development & manufacturing of cell & gene therapies - pushing the boundaries in cancer treatment & beyond. PharmaExecutiveMeeting (PEM), 15.10.2025, Basel, Schweiz
• Fricke S. Emerging solutions to existing challenges in CAR T cell manufacturing. Onkologie im Dialog, 19.9.2025, Chemnitz
• Fricke S. Expert circle - CAR T-cell therapy in Chemnitz  - achieving more together for our patients. Update Hämatologie 2025, 5.3.2025, Chemnitz
• Fricke S. Highlights/update EHA and ASCO CAR T cell therapy. Fokus Hämatologie - Highlights vom EHA/ASCO 2025, 2.7.2025, Chemnitz
• Fricke S. Management von CAR-T-Zellen - wie wir mit dem Immunsystem heilen können. Tumorakademie Südwestsachsen, 28.3.2025, Chemnitz 
• Fricke S. National strategy for gene and cell therapies: framework conditions and opportunities. Let’s X-Change – Fokus Onkologie 2025 I The future of hemato-oncological care in the Central German region, 8.1.2025, Leipzig
• Fricke S. Pioneering concepts for the manufacturing of advanced therapy medicinal products (ATMPs). 37. Tumorgenetische Arbeitstagung 2025, 9.5.2025, Leipzig 
• Fricke S. SaxoCell - pioneering cell and gene therapy from Saxony. Saxon Cancer Congress, 12.4.2025, Chemnitz
• Fricke S. T cell therapies – clinical stage of the art and current challenges. Webinar ESMI study groups of Oncoimmunology & Therapy and Chemistry, 17.12.2025
• Gebhardt C, Serfling R, Bär C, Lachmann N, Tretbar S. RNAvolution in CAR-T cell therapy: engineering circular, self-amplifying & trans-amplifying RNA. Fraunhofer CIMD Symposium "RNA-Based Therapeutics", 10.-11.9.2025, Hannover
• Gebhardt C, Serfling R, Bär C, Lachmann N, Tretbar S. RNAvolution in CAR-T cell therapy? Engineering circular, self- & trans-amplifying RNAs for transient CAR-T cell therapy. ESGCT/SETGYC Collaborative Congress, 7.-10.10.2025, Sevilla, Spanien
• Gebhardt C, Serfling R, Bär C, Tretbar S. RNAvolution in CAR-T cell therapy - optimizing RNA to generate transient CAR-T cells. From Lab to Life: Genome Editing Towards Therapies, DGGT, 10.-11.3.2025, Dresden
• Gebhardt C, Serfling R, Bär C, Tretbar S. RNAvolution in CAR-T cell therapy – optimizing RNA-based generation of CAR-T cells. Young Scientist Forum & FEBS congress 2025, 2.-5.7.2025  Sapanca / 5.-9.7.2025, Istanbul, Türkei
• Gutu D, Mytzka N, Arbaciauskaite S, Allelein S. Purity matters: developing robust EV separation workflows for immune-modulatory and biomarker applications. EVs in Immunity, 5.-7.11.2025, Athen, Griechenland
• Hennig K, Mattern K, Henrich D, Aerchlimann K, Henrich D, Schmiedel D, Makert G R, Fertey J, Friedrich-Stöckigt A, Selbmann F, Morschhauser A, Baum M, Kuhlmeier D. Innovative organ-on-chip Model systems with applications in cancer, neurology, and infectious diseases. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Hennig K, Mattern K, Henrich D, Aerchlimann K, Rajeh M.S.M, Morschhauser A, Baum M, Kuhlmeier D. Organ-on-chip platforms for one health applications and beyond. Chemnitzer Seminar: Sensor Systems for One Health, 2.-3.9.2025, Chemnitz
• Hennig K, Mattern K, Henrich D, Aerchlimann K, Rajeh MSM, Morschhauser A, Baum M, Kuhlmeier D. Integrated organ-on-chip systems for immuno-oncology and infectious disease research. MPS World Summit, 9.-13.6.2025, Brüssel, Belgien
• Herrmann A, Gege C, Hahn F, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, Ip WH, Weil T, Hunszinger V, Groß R, Heinen N, Pfänder S, Reuter S, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Grunwald T, Hietel B, Cynis H, Konzok S, Obernolte H, Dobner T, Münch J, Sparrer KMJ, Tenbusch M, Ensser A, Marschall M, Kohlhof H, Vitt D. Novel vidofludimus-based DHODH inhibitors containing carboxylic acid bioisosters with superior broad-spectrum antiviral activity. 34th Annual Meeting of the Coviety for Virology, 4.-7.3.2025, Hamburg
• Herrmann A, Gege C, Wangen C, Wagner S, Kögler M, Cordsmeier A, Irrgang P, Ip WH, Weil T, Hunszinger V, Groß R, Heinen N, Pfaender S, Reuter S, Klopfleisch R, Uhlig N, Eberlein V, Issmail L, Grunwald T, Hietel B, Cynis H, Münch J, Sparrer KMJ, Ensser A, Tenbusch M, Dobner T, Vitt D, Kohlhof H, Hahn F. Orally bioavailable RORγ/DHODH dual host-targeting small molecules with broad-spectrum antiviral activity. 34th Annual Meeting of the Coviety for Virology, 4.-7.3.2025, Hamburg
• Hudecek M. Accelerating CAR T-cell therapeutics with small molecules and CRISPR 2.0 gene editing. 7th International Workshop on CAR-T and Bispecifics iwCAR T congress, 11.04 bis 13.04.2025, Miami
• Hudecek M. CAR T for solid tumors. EHA-EBMT 7th European CAR T-cell Meeting, 6.-8.2.2025, Straßburg, 
• Hudecek M. Innovation in CAR T cell therapy of Multiple Myeloma. 51st Annual Meeting of the EBMT, 30.03.2025, Florenz 
• Hudecek M. Minicircle-based CAR-T: clinical applications. ESGCT, symposium hosted by PlasmidFactory
• Hudecek M. Molecular engineering of immune cells and in vivo gene transfer. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie DGHO, 24.10. bis 27.10.2025, Köln
• Hudecek M. Novel targets for CAR-T in MM. 6th Immune Effector Cell Therapies in Multiple Myeloma, 29.03.2025, Boston 
• Hudecek M. Secondary AML after CAR T cell treatment. Annual EHA meeting, 17.03 bis 20.03.2025, Malaga
• Hums R, Uhlig N, Issmail I, von Auw N, Warncke P, Hoffmann DS, Schoeder CT, Schrader S, Wüstenhagen D, Ramm F, Juchem M, Tretbar S, Grunwald T, Fertey J, Ulbert S. Cross-reactivity and protective efficacy of mRNA-lipid nanoparticle vaccines encoding diverse West Nile virus envelope protein variants in mice. 9th European Congress of Virology (ECV) 2025, 27.-30.4.2025, Dubrovnik, Kroatien
• Hums R, Uhlig N, Issmail L, von Auw N, Warncke P, Hoffmann DS, Schoeder CT, Schrader S, Wüstenhagen D, Ramm F, Juchem M, Tretbar S, Grunwald T, Fertey J, Ulbert S. Cross-reactivity and protection in mice with mRNA-lipid nanoparticle vaccine candidates encoding different West Nile virus envelope protein variants. 9th European Congress of Virology (ECV) 2025, 27.-30.4.2025, Dubrovnik, Kroatien
• Ivics Z. Advances in Sleeping Beauty transposon engineering of therapeutic cells. DG-GT Theme Day, 10.-11.3.2025, Dresden
• Ivics Z. Digging in the dirt: how archeogenetics and synthetic biology impacted gene therapy. ESGCT Spring School, 8.-11.4.2025, Potsdam
• Ivics Z. Enhanced efficiency of Sleeping Beauty transposon engineering of therapeutic cells by minicircle vectors. ESGCT Annual Congress, 7.-10.10.2025, Sevilla, Spanien
• Ivics Z. Gene therapy challenges and solutions. GSCN on Tour, 31.3.2025, Leipzig
• Ivics Z. Genetic engineering of therapeutic cells: challenges and solutions. 13th International mRNA Health Conference, 12.-13.11.2025, Berlin
• Ivics Z. Genetic engineering of therapeutic cells: challenges and solutions. Jahrestagung Deutsche Pharmazeutische Gesellschaft, 30.9.2025, Freiburg
• Ivics Z. Genetic engineering of therapeutic cells: challenges and solutions. Herbstsymposium, Rotes Kreuz, 28.11.2025, Wien, Österreich
• Ivics Z. Jumping genes for therapeutic cell engineering. Myeloma and Cell Therapy Workshop, 30.-31.10.2025, Ostrava, Tschechien
• Ivics Z. Mitigation of genotoxic risks in Sleeping Beauty transposon-engineered cells. Hungarian Molecular Life Science Conference, 28.-30.3.2025, Eger, Ungarn
• Ivics Z. Non-virally engineered advanced therapy medicinal products. IGLD, 6.-8.3.2025, Frankfurt am Main
• Kämpf C. Quality management in (research) software development. CDSN-Symposium, 18.11.2025, Leipzig
• Kebbel K. Qualification and validation – a versatile and efficient quality tool in the ATMP manufacturing (case study from an academic CDMO about a clinical phase I/II CAR-T cell product). Advanced GMP for ATMPs, 11.-12.6.2025, Wien, Österreich
• Kebbel K. When guidelines become a challenge (an experience report of an academic CDMO for ATMPs). Advanced GMP for ATMPs, 11.-12.6.2025, Wien, Österreich
• Kleinschmidt M. Elucidating binding mechanisms by using the frame inject command. Bruker Biosensors User Meeting, 17.-19.9.2025, Bremen
• Köhl U. Automated manufacturing of CAR effector cells: from viral to non-viral gene transfer. Cell Therapy Innovation Symposium, 9.10.2025, Oslo, Norwegen
• Köhl U. CAR effector cells: pushing the boundaries in cancer treatment switching from viral non non-viral gene transfer. Auftaktsymposium des Zentrums für Zell- und Gentherapie, 16.-17.1.2025, Freiburg/Br.
• Köhl U. CAR Effektor-Zellen: von der Krebstherapie zu Autoimmunerkrankungen. 15. Mitteldeutschen Neuro-Immunologie Forum 2025, 14.3.2025, Leipzig
• Köhl U. Entwicklung der Biotechnologie in Leipzig. 25 Jahre Biotechnologie-Offensive Sachsen, 12.6.2025, Leipzig
• Köhl U. From autologous to allogeneic CAR Effector cells: pushing the boundaries from cancer to other diseases. Dutch academic ATMP consortium DARE-NL, 19.9.2025, Utrecht, Niederlande
• Köhl U. From autologous to allogeneic CAR effector cells: pushing the boundaries from cancer to other severe diseases. 5th International Conference on Lymphocyte Engineering (ICLE), 20.-22.2.2025, München
• Köhl U. How to develop a new cell therapy – the success story of CAR T-cells. 10th German Pharm-Tox Summit, 26.3.2025, Hannover
• Köhl U. Innovationen und Herausforderungen im Bereich der Zell- und Gentherapie: Beispiel CAR-T-Zellen. Parlamentarisches Frühstück „Biotechnologieforschung in Deutschland", 27.6.2025, Berlin
• Köhl U. KI-unterstütztes Monitoring nach CAR-T-Zelltherapien. Kongress der Thüringer Chirurgen: "KI-Revolution in der Chirurgie: von Roboterchirurgie bis Virtual Reality", 16.5.2025, Suhl
• Köhl U. Living drugs - SaxoCell: cell and gene therapy. Germen Stem Cell Network on road, 31.3.2025, Leipzig
• Köhl U. Manufacturing and clinical application of CAR effector cells. Workshop "Frontiers in Drug Discovery", 6.-10.7.2025, Cres, Kroatien
• Köhl U. Manufacturing and treatment with CAR effector cells: from personalized to iPS-based off the shelf products and from viral to non viral gene transfer. GSCN-Jahrestagung, 15.-16.10.2025, Neuherberg
• Köhl U. Manufacturing and treatment with CAR effector cells: pushing the boundaries in cancer treatment and beyond. ISPE D/A/CH Future Leaders Days 2025, 3.11.2025, Wien, Österreich
• Köhl U. Manufacturing of CAR effector cells: from viral to non viral gene transfer. Deutsche Biotechnologie-Tage, 9.-10.4.2025, Heidelberg
• Köhl U. Neue Entwicklungen zum Engineering und Manufacturing bei zell-basierten Therapien. DGHO-Jahrestagung, 24.-27.10.2025, Köln
• Köhl U. Off the shelf cell therapy: Are NK cells the better option? ESMO Targeted Anticancer Therapies Congress (TAT), 3.-5.3.2025, Paris, Frankreich
• Köhl U. RNAuto – automated production of mRNA-based cell and gene therapeutics. 2. RNA-Therapeutika-Symposium, 10.-11.9.2025, Hannover
• Köhl U. Wenn Ethik auf Evidenz trifft: Was bedeutet Cross-Over für die Zukunft medizinischer Innovation? Future Medicine Innovation Days, 12.11.2025, Berlin
• Körtge A, Kamper C, Klinkmann G. In vitro assessment of catecholamine adsorption profiles during hemoadsorption therapy. European Society of Artificial Organs Conference (ESAO), Juni 2025, Enschede, Niederlande
• Kottwitz AK, Piechotta A, Schrempel S, Parthier C, Gnoth K, Geißler S, Linnert M, Morawski M, Kleinschmidt M, Roßner S, Rahfeld JU, Schilling S. Characterization of an antibody directed against a 3-nitrotyrosine-modified abeta. The Neuro4D Conference 2025, 19.-20.5.2025, Mainz
• Kreuz M. Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies. CCCG Research Retreat, 14.8.2025, Leipzig
• Kuhlmeier D, Schönfelder J, Heitor Lopes AL, Kölsch A, Allelein S. Revolutionizing targeted therapies: diagnostics and biomarker detection for precision medicine. Meet. Abstr. MA2025-01 2829. doi: 10.1149/MA2025-01602829mtgabs
• Kuhlmeier D. Extracellular vesicles and their potential for the aarly detection of neurodegenerative diseases. Vesicon 2025, Indian Extracellular Vesicles Society, 12.3.2025, Hyderbad, Indien
• Kuhlmeier D. Extracellular vesicles and their potential for the early detection of neurodegenerative diseases. Circulatory Biomarkers Workshop in Oncology and Neurology sponsored by Indo-German Science & Technology Centre (IGSTC), 9.3.2025, Hyderabad, Indien
• Kuhlmeier D. Revolutionizing targeted therapies: diagnostics and biomarker detection for precision medicine. 247th Electrochemical Society Meeting, 18.5.2025, Montreal, Kanada
• Kuhn C. Multimodale molekulare Analysen für lebende Arzneimittel. Diagnostica Forum 2025, 24.9.2025, Berlin
• Kuhn CK, Schmidt D, Selke J, Grau J, Rade M, Reiche K. LivingDrugOmics - optimized scRNA-seq omics workflow for high-resolution CAR T cell profiling. 6th Central German Bioinformatics Meeting, 2.–3.4.2025, Leipzig
• Kuhn CK, Schmidt D, Selke J, Rade M, Pham NN, Große F, Weirauch U, Fandrei D, Tretbar S, Löffler D, Blumert C, Fricke S, Köhl U, Merz M, Reiche K. A toolbox of wet- and dry-lab methods empowering seamless application of single-cell multi-omics for living drugs. 7th CAR T Cell Meeting, 6.-8.2.2025, Straßburg, Frankreich
• Loh B. Phage rivalry and receptor sharing in hypervirulent Klebsiella pneumoniae. Speaker invitation at the Université catholique de Louvain, 25.11.2025, Louvain, Belgien
• Loh B. Strategic receptor profiling optimizes phage therapy for K1 Klebsiella pneumoniae. 15th International Phages 2025, 1-.2.9.2025, Oxford, Vereinigtes Königreich
• Loh B. Strategic receptor profiling optimizes phage therapy for K1 Klebsiella pneumoniae. Workshop on personalized phage therapy: from lab to the patient (edition 2025), 27.-28.11.2025, Brüssel, Belgien
• Lopes A, Scholz P, Allelein S, Kuhlmeier D, Schäfer E, Wiener E, Saft B, Isserstedt-John N. Point-of-care solution for rapid monitoring of cytokine release syndrome by chemiluminescence cytokine detection on sensitive single photon avalanche diodes (SPAD) sensors. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Lopes A, Scholz P, Allelein S, Kuhlmeier D, Schäfer E, Wiener E, Saft B, Isserstedt-John N. Point-of-care solution for rapid monitoring of cytokine release syndrome by chemiluminescence cytokine detection on sensitive single photon avalanche diodes (SPAD) sensors. 35th Anniversary World Congress on Biosensors, 19.-22.5.2025, Lissabon, Portugal
• Makert GR, Bauer BU, Mertens-Scholz K, Hollwedel F, Ganter M, Knittler MR, Fertey J. COX-SAVE: development of a Coxiella burnetii secure advanced vaccine based on E-beam technology. International One Health Symposium, 13.-15.10.2025, Berlin
• Makert GR. Niederenergetische Elektronenstrahlung (LEEI) zur Inaktivierung von Pathogenen in Flüssigkeiten. Q-GAPS Workshop, 9.-10.12.2025, Sanitätsakademie der Bundeswehr, München
• Mattern K, Sandetskaya N, Kölsch A, Rau S, Menge A, Heinrich D, Allelein S, Hennig K. Additive manufacturing for the cost-efficient development of high-resolution, point-of-care diagnostic systems. Microprinting Conference 2025, 25.-27.8.2025, Bad Schandau
• Mattern K, Sandetskaya N, Kölsch A, Rau, S,  Menge A, Heinrich D. Technologies for a development and rapid prototyping of point-of-care diagnostic tests. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Mestermann K, Sanges C, Nießing B, Franz P, Rafiq Q, Klappa M, Kis T, Horna D, Juan M, Vrijhof B, Brandjes M, Schultz U, Nettleton D, Hudecek M. Automated manufacturing at point of care - the AIDPATH project. 5th International Conference on Lymphocyte Engineering (ICLE), 20.-22.2.2025, München
• Mestermann K. Blended Immunotherapies of CAR T Plus CAR macrophages to treat cancer and infection. 17th annual Protein and Natibody Engineering Summit Europe, 11.-13.11.2025, Lissabon, Portugal 
• Mestermann K. From bench to bedside: development of a virus-free clinical CAR T manufacturing protocol. 1st Maxcyte European User Group Meeting, 6.10.2025, Sevilla, Spanien
• Oliveira Da Rocha GH, Müller C, Przybylski-Wartner S, Schaller S, Riemschneider S, Lehmann J. Role of PPARg on anti-inflammatory effects mediated by AhR ligands in a Caco-2/THP-1 in vitro “in-flamed gut” model. 20th Congress ofthe European Crohn's and Colitis Organisation ECCO, 19.-22.2.2025, Berlin
• Pais RG, Leptihn S, Kuhlmeier D, Loh B. RecT: a phage-derived recombinase for ATP-independent in vitro isothermal point-of-care diagnostics. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Pais RG, Leptihn S, Loh B. The tale of pierceival: exploring the therapeutic potential of an R-type pyocin. 1st Danish Viruses of Microbes symposium, 11.-13.6.2025, Kopenhagen, Dänemark
• Podliian M. Phenotype of patient derived HNSCCs: from immortalized benchmarks to live tumor cultures. CCCG Forschungs-Retreat 2025, 14.-15.8.2025, Leipzig
• Rade M, Löffler-Wirth H, Kreuz M, Merz M, Alb M, Hudecek M, Köhl U, Reiche K. Development of a time series single-cell transcriptomic CAR T-cell atlas to explore the dynamics of CAR T-cell therapy. Mittelerde Meeting, 2.-3.4.2025, Leipzig
• Reiche K. Design specifications for virtual patient twins in engineered adoptive cellular immunotherapies. 8th course on Computational Systems Biology of Cancer, 22.-26.9.2025, Institut Curie, Paris, Frankreich
• Reiche K. Design specifications for virtual patient twins in engineered adoptive cellular immunotherapies. INSERM webinar in partnership with the International Research Data Alliance, the RDA; 26.9.2025, Paris, Frankreich 
• Reiche K. Digitale Zwillinge für lebende Arzneimittel. Herbsttreffen 2025: KI und Biotechnologie, DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V., 7.11.2025, Frankfurt a.M. 
• Ruetalo N, Dürrwald J, Benz M, Wiltzer-Bach L, Gomes YCP, Sow AA, Patten K, Chatel-Chaix L, Schöbel A, Herker E, Wilken L, Scaturro P, Yang S, Jans DA, Todt D, Nocke MK, Müller P, Uhlig N, Grunwald T, Gondim MV, Schorpp K, Hadian K, Günther M, Laufer S, Burnet M, Schindler M. Identification and characterization of a broadly acting Flavivirus capsid inhibitor. 9th European Congress of Virology (ECV) 2025, 27.-30.4.2025, Dubrovnik, Kroatien
• Sandetskaya N, Kölsch A, Mattern K, Kuhlmeier D. A seamless single-vial integration of a molecular test and lateral flow detection for point-of-care infection diagnostics. 14th European Congress on Tropical Medicine and International Health, 29.9-2.10.2025, Hamburg
• Sanges C. Beyond the hype: where can AI (actually) take CGT. Advanced Therapies Europe, 2.-4.9.2025, Barcelona, Spanien
• Sanges C. CAR-T cell therapy: advancing access or deepening disparities? 51st Annual Meeting of the EBMT, 30.3.2025, Florenz, Italien
• Sanges C. Innovative medicine manufacturing in the European Union. European Health Forum, 30.9.-3.10.2025, Gastein
• Sanges C. T2EVOLVE roundtable: advanced cellular therapies: collaborative approaches to preclinical innovation. EHA-EBMT 7th European CAR T-cell Meeting, 6.-8.2.2025, Straßburg, Frankreich
• Scheller L, Zhou X, Loeffler-Wirth H, Kreuz M, Kadel SK, Schimanski S, Schulze H, Ruckdeschel A, Eisele F, Konetzki V, Jornet Culubret M, Merz M, Mersi J, Waldschmidt J, Danhof S, Köhl U, Kortüm KM, Rasche L, Einsele H, Düll J, Topp MS, Hudecek M, Reiche K, Alb M. Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and adverse outcome of CAR-T therapy. 67th ASH® Annual Meeting, 6.-8.12.2025, Orlando, USA
• Schindler-Wnek K, Stahringer A, Heimer N, Köhl U, Fricke S, Schmiedel D. CAR NK cells show lower off-target risk than CAR T cells. ICLE, 20.-22.2.2025, München
• Schindler-Wnek K, Stahringer A, Heimer N, Köhl U, Fricke S, Schmiedel D. Divergent on-target off-tumor effects by CAR T and CAR NK cells. ESGCT Annual Congress, 7.-10.10.2025, Sevilla, Spanien
• Schindler-Wnek K. Advancing the development of safe and effective chimeric antigen receptor-based therapies. Webinar Cell Signaling Technology, 11.9.25
• Schmidt JR, Adamowicz K, Arend L, Lehmann J, List M, Poh PSP, Baumbach J, Kalkhof S, Laske T. A novel universal framework for proteomics: meta-analyses allows the identification of druggable targets, active factors, and biomarkers for bone biomaterial development. Jahrestagung der Deutschen Gesellschaft für Massenspektrometrie (DGMS), 4.-7.3.2025, Göttingen
• Schmiedel D. Dual antigen targeting by nanobody-based CAR-NK cells. preCDD Meeting (Krebshilfe), Hamburg, 3.7.2025
• Schmiedel D. Dual targeting NK cells against AML. CREATIC conference, 9.11.2025, Brno, Tschechien
• Schmiedel D. The next generation of allogeneic cell therapies. CARfactory meets Industry Day, 13.11.2025, Leipzig
• Schölzel A, Doss S, Heskamp J. Modulation of microglial activity by extracellular vesicles: a pathway to enhanced elimination of amyloid-β. ISEV 2nd Symposium on EVs in Nervous Systems, 29.-31.10.2025, Montreal, Kanada
• Schönfelder J. Non-invasive detection of cancer markers. CCCG Forschungs-Retreat 2025, 14.-15.8.2025, Leipzig
• Selpiev Z, Leptihn S, Müsken M, Loh B. Characterization of two Klebsiella pneumoniae phages for potential therapeutic applications. 1st Danish Viruses of Microbes symposium, 11.-13.6.2025, Kopenhagen, Dänemark
• Selpiev Z, Müsken M, Leptihn S, Loh B. Characterization of two Klebsiella pneumoniae phages for potential therapeutic applications. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig
• Serfling R, Degenhardt A, Franz P, Funkner A, Tretbar S. CAR FINDER: revolutionizing the screening process for CARs. 13th International mRNA Health Conference, 11.-13.11.2025, Berlin
• Serfling R, Degenhardt A, Franz P, Tretbar S. CAR FINDER: accelerating innovation in CAR T cell development. International Conference on Lymphocyte Engineering (ICLE), 20.-22.2.2025, München
• Serfling R, Degenhardt A, Franz P, Tretbar S. CAR FINDER: revolutionizing the screening process for CAR T cell therapies. ESGCT Annual Congress, 7.-10.10.2025, Sevilla, Spanien
• Silva Ferreira F. Combination of CAR-immune cells to overcome resistance mechanisms in solid tumors. DKH Präklinische Wirkstoffforschung - Konsortiumsmeeting preCDD, 3.-4.7.2025, Hamburg
• Silva Ferreira F. Combination of CAR-immune cells to overcome resistance mechanisms in solid tumors. DKH Präklinische Wirkstoffforschung -CARFactory Day, 15.11.2025, Leipzig
• Silva Ferreira F. From solo to duet: combining CAR-modified immune cells to overcome resistance mechanisms associated with cancer immunotherapy. EHA-EBMT 7th European CAR T-cell Meeting, 6.-8.2.2025, Straßburg, Frankreich
• Silva Ferreira F. From solo to duet: combining CAR-modified immune cells to overcome resistance mechanisms associated with cancer immunotherapy. Fraunhofer IZI PhD Day, 11.6.2025, Leipzig
• Smith D. Optimieren die Interaktionen mit der Virenoberfläche. Patentbörse auf dem Sächsischen Innovationstag, 25.6.2026, Dresden
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Microbiome-derived metabolites guide atient outcome prediction and CAR T cell engineering. EHA-EBMT 7th European CAR T-cell Meeting, 6.-8.2.2025, Straßburg, Frankreich
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Microbiome-derived metabolites to guide patient outcome prediction and CAR T-cell engineering. 7th International Workshop on CAR-T and Bispecifics iwCAR T congress, 11.-13.4.2025, Miami, USA
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Microbiome-derived postbiotics enforce cellular immunotherapy. 17th PEGS Europe Protein & Antibody Engineering Summit, 11.-13.11.2025, Lissabon, Portugal
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Microbiome-derived postbiotics integrate into CAR T cell metabolism and augment anti-tumor immunity. IUIS Congress and DGfI Annual Meeting, 17.-22.8.2025, Wien, Östterreich
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Of CARs and commensals - synergizing microbiome-derived postbiotics and T cell engineering. VIB Congress, 6.-7.11.2025, Lissabon, Portugal
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Synergizing microbial metabolites and cellular immunotherapy. IOLIN Congress - Immunooncology and local intervention, November 2025, München
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. Synergizing microbial metabolites and cellular immunotherapy. 3rd Young Scientist Cancer Congress Berlin, Oktober 2025, Berlin
• Staudt S, Ziegler-Martin K, Mangold K, Franz J, Hudecek M, Luu M. The role of the microbiome in cancer immunotherapy. ESH 3rd How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients, September 2025, Stockholm, Schweden
• Tretbar S. CAR FINDER - a platform for rapid CAR T cell screening and latest trends in CAR T cell development. Lonza Webinar, 7.7.2025
• Tretbar S. CAR FINDER - a platform for rapid CAR T cell screening. Lonza Webinar, 25.2.2025
• Tretbar S. CAR FINDER. 10. Leipziger Gründungsnacht, 18.11.2025, Leipzig
• Tretbar S. CIMD cell therapy platform - development of CAR T cells against non-malignnat diseases. Fraunhofer CIMD Symposium "RNA-Based Therapeutics", 10.-11.9.2025, Hannover
• Tretbar S. CIMD cell therapy platform - development of CAR T cells against non-malignnat diseases. Day of Immune Research CIMD, 21.11.2025, Frankfurt
• Tretbar S. Latest trends in CAR T cell development. Cytiva Pre-Event of ESGCT Annual Congress, 7.-10.10.2025, Sevilla, Spanien
• Tretbar S. mRNA-LNP technology for safe CAR cell therapy. ASGCT Annual Conference, 17.5.2025, New Orleans, USA
• Tretbar S. mRNA-LNP technology for safe CAR-T cell therapy. Cytiva Webinar, 4.12.2025
• Tretbar S. Peripheral immune tolerance - and what to do if the immune system fails? Weihnachtsvortrag Nobelpreis Medizin, 11.12.2025, Halle
• Uhlig N, Issmail L, Fertey J, Ulbert S, Grunwald T. Mouse models for neurotropic Flavivirus pathogenesis and infection studies. 9th European Congress of Virology (ECV) 2025, 27.-30.4.2025, Dubrovnik, Kroatien
• Ulbert S. Irradiated vaccines as a strategy to control zoonotic diseases and promote public health. Atoms for a healthy planet, 20.10.2025, Daejon, Südkorea
• Ulbert S. Irradiation technologies for vaccine manufacturing. World Vaccine Congress, 16.10.2025, Amsterdam, Niederlande
• Walia D, Schoenfelder J. Towards real-time COVID-19 detection via untargeted breath VOC profiling using online GC-IMS. Breath Summit, 14.-19.9.2025, Innsbruck, Österreich
• Walia D, Schoenfelder J. Towards real-time detection of COVID-19 via untargeted volatile organic compound profiling using online gas chromatography-ion mobility spectrometry. One Health Symposium, 13.-15.10.2025, Berlin
• Weirauch U, Kreuz M, Birkenbihl C, Alb M, Quaranta M, Calzone L, Orozco-Ruiz S, Binder S, Fischer L, Clavreul S, Maguri M, Ferle M, Rade M, Azarias G, Hydren JR, Jamarik J, Schwarz D, Sebestyen Z, Kuball J, Popp G, Antoine C, Knockaert M, Schoeder CT, Fandrei D, Sanges C, Radvilas V, Gagelmann N, Rückert M, Penack O, Fricke S, Schmidt A, Ward C, Steinbeisser C, van Gyseghem JM, Niarakis A, Garderet L, Hudecek M, Neumuth T, Platzbecker U, Köhl U, Demlova R, Kremer A, Franke S, Fröhlich H, Merz M, Reiche K. CERTAINTY - a cellular immunotherapy virtual twin for personalized cancer treatment. isi Health conference, 11.8.2025, Leuven, Belgien
• Weirauch U. CERTAINTY - a cellular immunotherapy virtual twin for personalized cancer treatment. NKSG Symposium Digital Health, 26.2.2025, Köln
• Weirauch U. CERTAINTY - a cellular immunotherapy virtual twin for personalized cancer treatment. CCCG Research Retreat, 14.8.2025, Leipzig
• Weirauch U. Vitrual twins - wie digitale Innovationen die Versorgung vorantreiben. WIP Tag der Versorgungsforschung, 18.9.2025, Köln
• Wiltzsch V, Dias DB, Schmidt JR, Chan WL, Lehmann J, Kirwan JA, Poh PS, Kalkhof S. Multi-omics profiling of bone regeneration in diabetes links healing impairment with increased mast cell activity. 18th Leipzig Research Festival for Life Sciences 2025, 30.1.2025, Leipzig